Antimicrobial resistance: A challenge awaiting the post-COVID-19 era

Autor: Aklilu Abrham Roba, Tekle Airgecho Lobie, Magnar Bjørås, Kirsten Skarstad, James Alexander Booth, Knut Ivan Kristiansen, Abraham Aseffa
Rok vydání: 2021
Předmět:
Microbiology (medical)
medicine.medical_specialty
Tuberculosis
Microbial DNA
DOTs
Directly Observed Treatment Strategy
Disinfectant
Antitubercular Agents
Drug resistance
Infectious and parasitic diseases
RC109-216
pharmaceuticals
WHO
World Health Organization
Antibiotic resistance
NDM1
New Delhi Metallo-β-lactamase 1
non-pharmaceuticals
Pandemic
Drug Resistance
Bacterial
Medicine
Humans
AMR
Intensive care medicine
Pandemics
Bacteria
business.industry
SARS-CoV-2
Public health
SARS-COV2
Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19
TB
Tuberculosis
General Medicine
medicine.disease
Anti-Bacterial Agents
Infectious Diseases
Perspective
TLS
Translesion Synthesis Polymerase
BAC
Benzalkonium chloride
business
HIV
Human Immunodeficiency Virus
Malaria
Disinfectants
DNA
Deoxyribonucleic Acid
Zdroj: International Journal of Infectious Diseases
International Journal of Infectious Diseases, Vol 111, Iss, Pp 322-325 (2021)
ISSN: 1878-3511
1201-9712
Popis: Microbe exposure to pharmaceutical and non-pharmaceutical agents plays a role in the development of antibiotic resistance. The risks and consequences associated with extensive disinfectant use during the COVID-19 pandemic remain unclear. Some disinfectants, like sanitizers, contain genotoxic chemicals that damage microbial DNA, like phenol and hydrogen peroxide. This damage activates error-prone DNA repair enzymes, which can lead to mutations that induce antimicrobial resistance. Public health priority programs that have faced drug-resistance challenges associated with diseases, such as tuberculosis, HIV, and malaria, have given less attention to risks attributable to the COVID-19 pandemic. Pathogen-specific programs, like the directly observed treatment strategy designed to fight resistance against anti-tuberculosis drugs, have become impractical because COVID-19 restrictions have limited in-person visits to health institutions. Here, we summarized the key findings of studies on the current state of antimicrobial resistance development from the perspective of current disinfectant use. Additionally, we provide a brief overview of the consequences of restricted access to health services due to COVID-19 precautions and their implications on drug resistance development.
Databáze: OpenAIRE
Externí odkaz: